Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

2,000 publications—and counting

To date, over 2,000 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

ASCO GU
February 2026
Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
McKay R, Li W, Roose J, et al.
ASCO GU
February 2026
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
Grande E, Bamias A, Wit, R, et al.
ASCO GU
February 2026
Treatment patterns and survival outcomes among lutetium 177-experienced patients with metastatic castration-resistant prostate cancer
tran B, Dorff T, Richey M, et al.
ASCO GU
February 2026
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with locally advanced/metastatic urothelial cancer
Smyth E, Richey M, Patel K, et al.
ASCO GU
February 2026
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
Patel K, Zhao D, Hankinson E, et al.
ASCO GU
February 2026
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
Hankinson E, Kerr B, Ward P, et al.
ASCO GI
February 2026
A feasibility analysis to align fit-for-purpose real-world data to emulate the AZUR-1single-arm clinical trial in patients with dMMR/MSI-H locally advanced rectal cancer
Roodhart J, O'Donnell S, Kalilani L, et al.
Gynecologic Oncology
December 2025
Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)
Shahin M, Mathur R, Parthan A, et al.
Blood Cancer Journal
December 2025
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies
Taylor L, Chen A, Pierre A.

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2026